Yesterday, I was joined in The Doctor’s Lounge by Professor Dorit Reiss, Dr. Demetre Daskalakis, and Dr. Angela Rasmussen (who I’m grateful was able to join us on short notice). This all-star panel discussed the science, legality, and politics of the Trump administration’s sudden changes to the CDC’s pediatric vaccine schedule for the United States, a dramatic shift that occurred outside of the usual transparent processes.
Topics covered include:
Why it matters that the move bypassed the ACIP’s evidence-based, transparent process.
Why we are not so impressed with Senator Bill Cassidy’s reaction to this move. (Recall that Cassidy was bamboozled by Robert F. Kennedy Jr. who, in exchange for a vote to confirm him as HHS Secretary, promised that he would not make changes to the nation’s vaccine schedule.)
What this all means legally under administrative law.
How the administration’s co-opting and redefining of the term “shared clinical decision-making” will likely undermine vaccine confidence and uptake.
Specifics on some of the changes to the vaccine schedule, including why a few of these changes might have been defensible had the actual rigorous processes that RFK Jr. has dispensed remained in place.
An in-depth summary with timecodes can be found below. I hope you find this session informative, and please join me in thanking our panelists!
Closed captions (㏄) for the above video and a transcript option (📄) can be found beneath the video playback control bar above.
Quick reminder that this is all entirely free for everyone, thanks to the subset of people who upgrade to premium. If you’d like to support this work, here’s how👇
Summary & Highlights.
Aided by ChatGPT.
(00:31) Welcome, stakes, and why we’re doing this
We open by laying out what happened “in the past 24 hours”: Secretary Kennedy unilaterally scaled back the U.S. childhood vaccine schedule—without the usual evidence-driven, public, ACIP-centered process—and we frame this as a direct risk to kids and to the governance system that underpins public health.
(01:14) The panel and immediate chaos
We introduce our panel—Professor Dorit Reiss, Dr. Angie Rasmussen, and Dr. Demetre Daskalakis—while dealing with tech issues that keep knocking audio/video offline. The interruptions become a running reminder of how much of this moment feels improvised and unstable—exactly what we don’t want in national vaccine policy.
(02:06) The NYT framing: “17 diseases to 11 overnight”
We anchor the discussion in Apoorva Mandavilli’s reporting and the core shock: the schedule appears to drop coverage from prevention of 17 diseases to 11 essentially overnight. We emphasize that this wasn’t a normal scientific or regulatory update—it was a political act presented as public health.
(02:39) Why the messenger matters: Jim O’Neill and “effective immediately”
We zoom in on the announcement being delivered as “effective immediately” via Acting CDC Director Jim O’Neill—whom we characterize as a political appointee without the scientific or clinical standing to adjudicate population-level immunization policy. The meta-problem: the administration is using the CDC’s credibility as a delivery vehicle for decisions made elsewhere.
(03:25) This isn’t about “mandates”
We underline a point that will keep coming up: rolling back the CDC schedule is not the same thing as rolling back state vaccine mandates. States still control school requirements and emergency powers. The move is about federal guidance, insurance dynamics, liability, access, and—critically—trust and confusion.
(04:09) Bill Cassidy “rips” RFK Jr.—and why we’re not impressed
We discuss reporting that Senator Bill Cassidy criticized the schedule change as lacking scientific input—and we say plainly: Cassidy helped put Kennedy in this job, so performative concern now rings hollow. The broader theme: some “checks” are arriving only after the damage is underway.
(05:04) The lead-up: pulling back vaccine reporting requirements
We flag a broader pattern: administrative moves that reduce visibility into vaccination rates (for example, CMS-related reporting changes), making it harder to track what’s happening in real time—especially across states with different political climates and baseline uptake.
(05:39) Demetre on process: “data were provided, then… silence”
Dr. Daskalakis explains what the “consulted career scientists” claim looks like from the inside: NCIRD staff were asked for a landscape comparison of international schedules, provided it, and then never got meaningful input into the final product. The result shows obvious “schedule-writing” errors—suggesting experts weren’t in the room when decisions were finalized.
(07:06) Two authors, no process
We outline the core procedural indictment: a massive national guidance shift appears to hinge on a justification document written by two people—without peer review, without public comment, and without the standard ACIP mechanism. Even if the authors had been unimpeachable, the process would still be unacceptable for a serious public health system.
(08:10) The HHS justification document: vibes dressed up as evidence
We discuss the released/leaked PDF written by Dr. Tracy Beth Høeg and Dr. Martin Kulldorff and describe the structure we’re seeing: non sequiturs, rhetorical gestures (“vaccines work, but…”) and a trust narrative that doesn’t grapple with vaccine-by-vaccine risk–benefit analysis.
(09:44) The clinical community says “this is bad”
We note the uniformity of opposition from major medical organizations (AAP, IDSA, ACEP, and others). The point isn’t “appeal to authority”—it’s that the people who both study these questions and take care of the downstream consequences are warning that this is reckless.
(10:10) Dorit Reiss: Is it legal? “Probably not—if it gets reviewed on the merits”
Professor Reiss separates the issue into two big legal vulnerabilities:
Process problem: even if the Secretary has authority to override ACIP, he likely must go through ACIP in a meaningful way—more than a single discussion with no vote and no formal committee rationale.
Arbitrary-and-capricious problem: under administrative law, the government needs a coherent explanation connecting evidence to decisions, addressing key factors Congress intended, and explaining why it is changing an existing policy—especially when the original policy was built on far more robust deliberation.
(11:53) “Arbitrary and capricious,” translated
We walk through what courts generally expect: address major issues, rely on relevant factors, show plausible fact-finding, and connect facts to decisions. When changing policy, you must explain why the old policy is wrong—not just gesture at a new narrative.
(12:58) The “peer nations” dodge
We hit a specific weakness in the “Denmarkify the U.S.” framing: the administration doesn’t explain why selected countries are true peers given structural differences (universal coverage, paid leave, child poverty rates, demographics, and healthcare access). If you’re going to borrow another country’s schedule, you have to explain why the comparison holds.
(13:40) You can’t just “de-schedule” without vaccine-by-vaccine justification
We emphasize: to survive review, you’d expect a vaccine-by-vaccine analysis—risk, benefit, burden, feasibility, equity, implementation realities. The critique isn’t that the document did this poorly. It largely didn’t do it seriously.
(14:00) The trust argument backfires
We argue that a secretive, cursory, unilateral process predictably reduces trust. If the stated goal is rebuilding public confidence, this method is self-defeating on its face.
(15:32) Angie: surprised—but also not
Dr. Rasmussen says the move is startling in scale, but consistent with the broader “throw everything at immunization and see what sticks” approach: attempt multiple destabilizing moves, accept that some will fail, and keep pushing new ones.
(16:33) “Trust” as a pretext
Angie dismantles the trust rationale: holding a press conference with minimal notice, rolling out irregular guidance, and pointing to a backroom document as justification isn’t how you rebuild confidence. She frames the “trust” story as hand-waving designed to rationalize a predetermined outcome.
(18:12) Angie’s rabbit hole: ACIP minutes from 1964
Angie describes pulling the earliest ACIP minutes she could find and being struck by how transparent the committee was from the start—down to explicit commitments to ongoing safety monitoring. The contrast is the point: transparency wasn’t a late invention; it was foundational.
(20:47) What’s actually eroding trust
Angie argues the trust collapse isn’t primarily about public health officials “messing up” during the pandemic—it’s that today’s leaders and allied voices are actively lying about vaccines, scientists, and public health, and then pointing to the resulting skepticism as evidence that the system must be torn down.
(22:04) Trump’s post: he’s not “sitting it out”
We bring up a Trump post celebrating the schedule change and congratulating Kennedy, Marty Makary, Mehmet Oz, and Jay Bhattacharya. We explain why this matters: it signals that Kennedy is not seen as a liability inside the administration—at least not right now.
(23:24) Are Makary/Oz/Bhattacharya involved—or just being used?
Angie’s read: even if involvement varies, the public signal is the point—“everyone is on board.” She also notes reporting/rumors of internal tension, but observes that Makary’s proximity to the announcement suggests at least some level of participation or acquiescence. [Note: I later learned that these three were actually deeply involved in this process. I’ll discuss this tomorrow.]
(25:30) No more benefit of the doubt
Angie pushes back on “they came in with good intentions”: whatever their initial framing, they’ve made choices since taking office. If staying in power requires signing onto destabilization, they’re doing it.
(27:33) What “normal times” would look like
We outline what would ordinarily happen for a decision of this magnitude: a structured interagency process, evidence review, a decision memo, documented sign-offs, and implementation planning. Instead, this was routed through CDC “soft guidance” to create a veneer of legitimacy while shifting accountability onto CDC.
(29:53) Why the missing CDC nominee matters
We discuss the strategic advantage of leaving CDC leadership in “acting” status: it enables control through interim leadership windows, procedural gamesmanship, and internal power structures (including a principal deputy) while avoiding Senate scrutiny.
(31:52) The Evidence Collective’s rapid breakdown
We highlight a fast, practical comparison document showing old U.S. guidance, the new posture, and other countries’ schedules—plus epidemiologic context. It becomes a bridge from process/legal talk back into concrete science.
(32:18) RSV immunization: the monoclonal antibody that gets misrepresented as a “vaccine”
We pivot to one of the most consequential and confusing pieces: RSV prevention in infants. We stress that nirsevimab is a monoclonal antibody—immediate passive protection—not a traditional vaccine. The “denial-to-minimization” pattern shows up here: RSV was once invoked to downplay COVID risks for kids; now RSV is minimized too.
(33:21) Demetre on nirsevimab: supply, scale-up, and real-world impact
Demetre summarizes the initial season as supply-constrained and messy—but describes the typical collaborative fix (CDC/FDA/manufacturer scaling production). The subsequent season saw much better supply and meaningful reductions in RSV burden.
(35:16) The “death imbalance” spin
We address a key rhetorical tactic: cherry-picking numerical imbalances in deaths across trial arms to imply danger. Demetre explains why this can be misleading (including 2:1 randomization and deaths unrelated to the product—underlying conditions, trauma, etc.). The broader point: creating fog around clear benefits.
(36:29) The schedule errors reveal the absence of experts
Demetre calls out logistical incoherence: RSV monoclonal antibodies appear twice, classified in ways that don’t map onto how clinicians actually decide who should get what and when. That kind of mistake is exactly what happens when schedule design is done without the people who do it for a living.
(37:39) “High-risk only” doesn’t work well in pediatrics
We stress a central epidemiologic reality: in kids, many severe outcomes occur in children without known risk factors. You often discover “high risk” after catastrophe hits. Demetre notes that ACIP data show a large share of RSV hospitalizations occur in children without underlying conditions—making “risk-only” strategies predictably leaky.
(40:20) Base rates and the rhetorical trap
We walk through the logic problem: because there are so many healthy kids, a majority of hospitalized children can be “previously healthy” even when individual risk is higher among those with comorbidities. That’s not an argument against broad prevention; it’s a reason broad prevention can make sense when the intervention is safe and effective.
(41:28) Long-term harms: selective skepticism
We call out a double standard: exaggerated uncertainty about long-term vaccine effects paired with indifference about long-term harm from severe pediatric respiratory disease and ICU care. If we’re going to demand long-horizon evidence, we can’t ignore the long-horizon consequences of preventable illness.
(42:38) Precedent: “abundance of caution” can boomerang
We reflect on earlier moments where institutions made concessions without strong evidence (for example, removing thimerosal “to appease the masses”), creating future rhetorical ammunition: “Even they admitted there was a problem.” The lesson: precaution without clear grounding can become a weapon later.
(44:00) Moving goalposts as the core strategy
We name the pattern: risk stratification is praised when it shrinks eligibility and condemned when it expands it. “Gold standard science” is invoked selectively. The consistent endpoint is reduced access to vaccines and immunizations.
(46:22) Shared clinical decision-making sounds nice—until you know what it signals
We explain why “shared clinical decision-making” isn’t neutral in practice: clinicians hear it as “the disease isn’t serious enough” or “the product has enough downside that we’re not making a routine recommendation.” It’s a signal, and it predictably shapes uptake.
(47:10) Dorit on AAP v. Kennedy: the standing breakthrough
We shift to the AAP lawsuit challenging Kennedy’s COVID vaccine recommendation changes and, crucially, the standing problem. Dorit explains that courts require concrete injury—not abstract disagreement. The judge accepted AAP’s theory of organizational harm (resources diverted, counseling burdens, coverage/consultation dynamics) and allowed the case to move forward.
(49:45) Why this matters: it creates a path for future challenges
Even if this isn’t binding precedent, it’s a practical roadmap. If judges adopt similar reasoning, organizations may be able to establish standing to challenge broader schedule changes—despite the administration’s efforts to insulate the move by leaving insurance coverage and liability formally intact.
(50:58) Discovery and speed: courts aren’t a sports car
We set expectations: lawsuits take time to write well; temporary restraining orders can be fast, but the system moves slowly. The harm here may be gradual—confusion, uptake declines, state-level policy pressure—rather than an immediate “axe falls today” moment.
(55:24) VFC and HPV: where “guidance” turns into access
Demetre flags a concrete, immediate access issue: HPV recommendation changes can affect what insurers must cover and what VFC can provide at certain ages. We discuss how “routine recommendation” status interacts with ordering rules, stocking decisions, and whether practices choose to carry expensive products—especially when VFC participation comes with operational requirements.
(56:03) The tragedy: real scientific de-escalation questions now get poisoned
We make a key distinction: there are legitimate questions about dose de-escalation for some vaccines under specific circumstances. Those are exactly the kinds of topics ACIP should openly debate with public input. Doing it abruptly, politically, and opaquely undermines public willingness to accept even evidence-supported simplifications later.
(58:00) Call to action: share, amplify, and don’t give up
We explicitly ask viewers to share the session to “hack the algorithm” and spread expert context. The message: the public deserves real transparency, not top-down decrees.
(58:47) The chilling effect on vaccine science
Angie closes with the downstream academic damage: infectious disease and vaccine research cuts shrink training pipelines and hollow out expertise. We point out the looming paradox: we spent decades reducing diseases like measles and polio to the margins of active research—and now we may need a new generation of specialists just as funding and infrastructure are being dismantled.
(01:02:29) Why we keep doing this
We end on the idea that the point of these forums is to activate people and reclaim science as something that should be boring, transparent, and nonpartisan. We quote the moral center: vaccines helped make “childhood routinely survivable.” We’re not going back—unless we let it happen.
If you have information about any of the unfolding stories we are following, please email me or find me on Signal at InsideMedicine.88.
